Company research
RIGEL PHARMACEUTICALS INC
CIK 1034842Updated Sep 24, 2026
SecurityRIGL · NASDAQ · equity
Name history
RIGEL PHARMACEUTICALS INC · through Sep 3, 2026
RIGL price & chart
Loading TradingView…
NASDAQ:RIGL on TradingView ↗About the company
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
In the news
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update News provided by Rigel Pharmaceuticals, Inc. Nov 04, 2025, 16:01 ET Share this article Share to X Share this article Share to X Third quarter 2025 total revenue of approximately $69.5 million, including record net produc ↗
Seeking Alpha
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow ↗
Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow ↗
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 513,594,000Source | 163,976,000Source | 117,225,000Source | 134,279,000Source |
| Property, Plant and Equipment, NetUSD | 30,000Source | 92,000Source | 165,000Source | 857,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 40,580,000Source | 56,746,000Source | 32,786,000Source | 24,459,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 51,763,000Source | 41,615,000Source | 30,550,000Source | 40,320,000Source |
| Inventory, NetUSD | 11,506,000Source | 6,002,000Source | 5,522,000Source | 9,118,000Source |
| Assets, CurrentUSD | 240,166,000Source | 135,103,000Source | 99,266,000Source | 115,903,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 21,942,000Source | 10,165,000Source | 6,261,000Source | 8,259,000Source |
| Operating Lease, Right-of-Use AssetUSD | 920,000Source | 246,000Source | 861,000Source | 1,930,000Source |
| Other Assets, NoncurrentUSD | 1,908,000Source | 1,435,000Source | 3,055,000Source | 640,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 122,114,000Source | 160,688,000Source | 145,869,000Source | 147,895,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 18,000Source | 18,000Source | 175,000Source | 174,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,023,041,000Source | -1,390,065,000Source | -1,407,550,000Source | -1,382,459,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 181,000Source | 10,000Source | 8,000Source | -153,000Source |
| Stockholders' Equity Attributable to ParentUSD | 391,480,000Source | 3,288,000Source | -28,644,000Source | -13,616,000Source |
| Additional Paid in Capital, Common StockUSD | 1,414,322,000Source | 1,393,325,000Source | 1,378,723,000Source | 1,368,822,000Source |
| Liabilities and EquityUSD | 513,594,000Source | 163,976,000Source | 117,225,000Source | 134,279,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 99,237,000Source | 63,299,000Source | 53,267,000Source | 65,211,000Source |
| Operating Lease, Liability, CurrentUSD | 614,000Source | 285,000Source | 692,000Source | 1,133,000Source |
| Accounts Payable, CurrentUSD | 7,191,000Source | 3,339,000Source | 7,142,000Source | 22,508,000Source |
| Operating Lease, Liability, NoncurrentUSD | 395,000Source | — | 285,000Source | 972,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 39,981,000Source | 39,944,000Source | 42,264,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 155,012,000Source | 77,321,000Source | 56,933,000Source | 58,206,000Source |
| Long-term DebtUSD | 52,500,000Source | 60,000,000Source | 60,000,000Source | 40,000,000Source |
| Short-term InvestmentsUSD | 114,375,000Source | 20,575,000Source | 24,147,000Source | 33,747,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 367,024,000Source | 17,485,000Source | -25,091,000Source | -58,573,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,415,000Source | 2,228,000Source | 1,238,000Source | 998,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,711,000Source | 12,393,000Source | 8,806,000Source | 12,385,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 10,148,000Source | 11,065,000Source | -9,770,000Source | 24,848,000Source |
| Increase (Decrease) in InventoriesUSD | 5,635,000Source | -764,000Source | -1,172,000Source | 2,377,000Source |
| Increase (Decrease) in Accounts PayableUSD | 3,852,000Source | -3,803,000Source | -366,000Source | 3,788,000Source |
| Deferred Income Tax Expense (Benefit)USD | -245,852,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 75,655,000Source | 31,471,000Source | -5,743,000Source | -73,758,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -92,365,000Source | 4,130,000Source | -4,297,000Source | 72,777,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 450,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 601,000Source | -11,641,000Source | 18,367,000Source | 6,550,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 40,637,000Source | 56,746,000Source | 32,786,000Source | 24,459,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,573,000Source | 7,039,000Source | 5,848,000Source | 2,495,000Source |
| Income Taxes Paid, NetUSD | 1,063,000Source | 331,000Source | — | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | 700,000Source | 700,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 12,711,000Source | 12,393,000Source | 8,806,000Source | 12,385,000Source |
| Amortization of Intangible AssetsUSD | 2,400,000Source | 2,100,000Source | 1,100,000Source | 100,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 155,012,000Source | 77,321,000Source | 56,933,000Source | 58,206,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 0Source | 79,000Source | -266,000Source | — |
| Income Tax Expense (Benefit)USD | -245,197,000Source | 881,000Source | — | — |
| InterestExpenseNonoperatingUSD | 7,320,000Source | — | — | — |
| Investment Income, InterestUSD | 3,681,000Source | 2,092,000Source | 2,272,000Source | 684,000Source |
| Net Income (Loss) Attributable to ParentUSD | 367,024,000Source | 17,485,000Source | -25,091,000Source | -58,573,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 367,024,000Source | 17,485,000Source | -25,091,000Source | -58,573,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 294,282,000Source | 179,278,000Source | 116,882,000Source | 120,242,000Source |
| Cost of RevenueUSD | 19,621,000Source | 18,647,000Source | 7,110,000Source | 1,749,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 115,900,000Source | 113,059,000Source | 105,741,000Source | 112,451,000Source |
| Operating Income (Loss)USD | 125,466,000Source | 24,192,000Source | -20,491,000Source | -55,550,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 121,827,000Source | 18,366,000Source | -25,091,000Source | -58,573,000Source |
| Income Tax Expense (Benefit)USD | -245,197,000Source | 881,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 367,024,000Source | 17,485,000Source | -25,091,000Source | -58,573,000Source |
| Earnings Per Share, BasicUSD per share | 20.4Source | 0.99Source | -0.14Source | -0.34Source |
| Earnings Per Share, DilutedUSD per share | 19.48Source | 0.99Source | -0.14Source | -0.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 17,987,000Source | 17,579,000Source | 174,017,000Source | 172,406,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 18,840,000Source | 17,687,000Source | 174,017,000Source | 172,406,000Source |
| Interest Expense (non-operating)USD | 7,320,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,400,000Source | 2,100,000Source | 1,100,000Source | 100,000Source |
| Costs and ExpensesUSD | 168,816,000Source | 155,086,000Source | 137,373,000Source | 175,792,000Source |
| Current Income Tax Expense (Benefit)USD | 655,000Source | — | — | — |
| Interest ExpenseUSD | — | 7,918,000Source | 6,872,000Source | 3,707,000Source |
| Investment Income, InterestUSD | 3,681,000Source | 2,092,000Source | 2,272,000Source | 684,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 367,024,000Source | 17,485,000Source | -25,091,000Source | -58,573,000Source |
| Research and Development ExpenseUSD | 33,295,000Source | — | — | — |
Filing attachments
tm2533140d1_ex99-1.htm · 8-K · 2025-12-10
EX-99.1 2 tm2533140d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD…
Read attachment ↗tm2530133d1_ex99-1.htm · 8-K · 2025-11-04
EX-99.1 2 tm2530133d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million of net income in the third quarter of 2025 Completed enrollment in the dose escalation phase and enrolled the first patient in the dose expansio…
Read attachment ↗tm2522417d2_ex99-1.htm · 8-K · 2025-08-05
EX-99.1 2 tm2522417d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDS Genera…
Read attachment ↗tm2514128d1_ex99-1.htm · 8-K · 2025-05-06
EX-99.1 2 tm2514128d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports First Quarter 2025 Financial Results and Provides Business Update First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatmen…
Read attachment ↗tm2510607d1_ex99-1.htm · 8-K · 2025-03-27
EX-99.1 2 tm2510607d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Announces Settlement Agreement Resolving TAVALISSE ® (fostamatinib disodium hexahydrate) Patent Litigation SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively “Annora”) resolving patent litigation related to Rigel’s product TAVA…
Read attachment ↗tm258144d1_ex99-1.htm · 8-K · 2025-03-04
EX-99.1 2 tm258144d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 mill…
Read attachment ↗